Wanted to write this up because the oral vs injected BPC-157 debate online is mostly mechanism arguments and very little side-by-side from the same person, so take it as n=1 with all the caveats. Steel-manning the subq camp first: stability data on oral BPC in human GI fluid is genuinely thin, and the rodent work that gets cited for systemic effects mostly used injected. If your target tissue is a tendon or anything outside the gut, I think the subq argument is the stronger one on first principles. My own use was specifically for low-grade gut stuff post a course of antibiotics last autumn. Did roughly 6 weeks oral (500mcg twice daily, capsules from a UK compounder), washed out for 10 days, then 6 weeks subq at 250mcg/day into the abdomen. What I noticed, being honest with myself: - Oral: bloating settled in the ballpark of week 3. Stools more formed. Sleep unchanged.
- Subq: similar gut effect, maybe a touch faster, but I also slept noticeably better which I did not expect. What would change my mind: a proper crossover trial with a real placebo arm. Until then I’d call sleep effect a hypothesis, not a finding. Anyone run something similar w/ a cleaner protocol?
the order effect is what I’d push on first. oral ran weeks 1-6, washout was 10 days, subq ran weeks 7-12. post-antibiotic gut recovery has its own clock that runs months on its own, and a lot of the dysbiosis literature has people back near baseline somewhere in the 8-12 week range without any intervention. so the subq arm sitting on top of “further along in spontaneous recovery” is a confound you can’t separate from “subq works faster,” and 10 days isn’t a meaningful washout against a process operating on that timescale. the case for the sleep finding being real is fair, you noticed something you weren’t expecting, which usually argues against pure expectancy. but you also moved the injection site to the abdomen at the same time you moved the route, and subq dosing alone changes evening routine in a way oral capsules don’t. either of those could be doing it before you reach for a tissue-level mechanism. fwiw I’d want sleep architecture data, not just self-report, before calling it a hypothesis worth testing. duration and architecture are different variables and the difference matters for whatever mechanism you’d propose. ymmv.
eta: one more thing
Order effect is the strongest objection here and I don’t have a good answer to it. Conceding the washout was too short against a months-long recovery curve. On the sleep piece, fair, “duration and architecture are different variables” is the right pushback, self-report is weak evidence for either.
the concession on order effect is the right one, but I’d push further on the oral arm itself. case for treating it as a real comparator is fair, gut is the one tissue where local exposure makes the bioavailability question less fatal than it is for tendon or anything systemic. but you still haven’t separated “oral BPC did something” from “post-abx gut recovery on its own clock plus six weeks of time.” the subq arm at least has subq data behind it. the oral arm might be closer to placebo + time than a second condition. ymmv.
the part I’d push on is calling the sleep effect a hypothesis without first ruling out the obvious confound. you switched compound delivery AND injection site stimulus AND timing of dose all at once between the two arms, and subq into the abdomen at a consistent daily clock is itself a behavioral cue that can shift sleep architecture independent of any peptide effect. the actually diagnostic question isn’t oral vs subq for sleep, it’s whether the sleep delta tracks dose timing relative to slow wave onset. ymmv but i’d want a saline subq arm before calling it even a clean hypothesis.
not engaging the oral vs subq frame again because I already replied upthread on the sleep confound. different angle worth flagging: the variable nobody in these post-antibiotic BPC writeups isolates is which antibiotic, and that’s doing more work in the recovery curve than most people credit. a course of amoxicillin clears differently than azithromycin, which clears differently than a fluoroquinolone, and the gut wall and microbiome insults are not the same class of injury. fluoroquinolones in particular hit mitochondrial function in enterocytes on top of the microbiome shift, which is a different repair problem than what BPC’s proposed gastric activity is mostly aimed at. second piece: the natural recovery curve for a disrupted microbiome post broad-spectrum is long. there’s published work showing community composition still measurably off baseline at 6 months for some taxa after a single course, with bifidobacterium and akkermansia among the slower returners depending on the agent. if your “low-grade gut stuff” started in autumn and you ran oral through, say, mid-winter, the week 3 bloating settling lines up with a window where spontaneous recovery is already accelerating regardless of compound. doesn’t mean BPC did nothing, just means the null hypothesis here isn’t placebo, it’s “you’d have improved on roughly that timeline anyway.” the actually diagnostic thing if you wanted to tighten this up next time would be a stool sample at baseline and at the oral/subq crossover, even a consumer-grade 16S panel. it won’t tell you BPC’s effect cleanly but it’ll at least tell you where in the recovery curve you were when you flipped delivery routes, which is the variable you’re currently blind to. ymmv on which lab, the consumer panels have known reproducibility issues for low-abundance taxa, but you’re tracking large shifts at the phylum/family level which is where they’re least bad. fwiw the methodology of running it back-to-back on yourself with a real washout is better than what most people post, even if the underlying microbiome state was moving the whole time. just worth knowing what else was on the clock alongside the compound.
the sleep delta is the part I’d flag too, but I’d put a different hypothesis on the pile before pentadecapeptide-on-sleep: 10 days isn’t really a washout for whatever gut-microbiome shift the oral arm kicked off, and post-abx recolonization curves run on weeks-to-months, so the subq arm inherited a different baseline. tryptophan availability tracks gut state more than people credit. doesn’t rule out a direct effect, just means the crossover would need a much longer washout (or randomized order across multiple subjects) before sleep gets pinned on the route.
the piece I’d add that nobody’s flagged yet: post-antibiotic gut recovery has its own timeline that runs roughly 4 to 8 weeks for bile acid pool reconstitution and SCFA production from the bacterial side, and that curve is more or less independent of whatever peptide you put on top of it. so when you say “bloating settled ballpark of week 3” on oral, you’re measuring BPC plus whatever your microbiome was doing anyway on the recovery slope from the antibiotic course last autumn. the 10-day washout is fine for clearing BPC out of plasma, it’s nowhere near long enough for the background gut recovery curve to be in the same state at the start of arm two as it was at the start of arm one. which means arm two starts on a more recovered baseline, and a “touch faster” effect on subq is exactly what you’d expect even if the two routes were truly equivalent. not saying the subq isn’t doing something, just that the order effect alone predicts your direction. the sleep finding is more interesting to me than the gut piece because there’s animal data on BPC having direct vagal nerve interaction, not just downstream growth factor stuff, and the vagal afferent route is plausibly how a gut-targeted intervention bleeds into sleep architecture. abdominal subq with proximal delivery to vagal-innervated tissue is a different exposure profile than oral surviving gastric pH, so it’s at least mechanistically coherent that subq would hit that signaling path harder. still a hypothesis like you said, but if you ever do run it again, randomising the order across two participants (one oral first, one subq first) gets you a cheap-ish way to separate the route effect from the background recovery curve without needing a placebo arm. wouldn’t be a real crossover but it’d at least decouple the order confound, which is the bigger problem here imo.
the sleep delta on subq is the part worth digging into, because the most plausible non-placebo mechanism isn’t even gut. BPC has documented vagal interaction in the animal lit, not just downstream growth factor effects, and subq abdominal delivery is going to have a different exposure profile to vagal afferents than an oral capsule that’s getting chewed up by gastric proteases before it ever reaches the small bowel. so “similar gut effect, better sleep” is actually consistent with the vagal-route hypothesis even before you invoke placebo, and i think that’s the more interesting confound than the trial-design one. the other thing your protocol can’t separate is the post-antibiotic recovery curve underneath both arms. bile acid pool and short-chain fatty acid production from a depleted microbiome typically reorganize over a 4 to 8 week window post abx, which means your week 3 bloating improvement on oral is sitting right on top of the timeline you’d expect from doing nothing. doesn’t mean the BPC didn’t help, but the order matters: oral first, then washout, then subq means the subq arm got the benefit of an already-partly-recovered baseline. a coin flip on which arm goes first would tighten that up, though you’d need a longer washout than 10 days to really call it clean ime. on the crossover design you’re asking for: even without placebo, the move that would sharpen this is running the same compound on alternating days within an arm and seeing whether the gut effect tracks the dose calendar or just keeps trending regardless. if bloating keeps improving on the off days that’s the recovery curve doing the work. if it stalls on off days and resumes on dose days, the signal is real. cheap, no compounder needed, and it answers the “is this me or the peptide” question better than a placebo arm you can’t actually source.
the wash-out length is the piece i’d push on. ten days is enough for plasma clearance but not enough to reset tissue exposure if the subq arm is putting BPC into gut-adjacent tissue from an abdominal pin. you ran two arms with overlapping tissue exposure on the second one, so the “subq worked a touch faster” read could be carryover from the oral cycle still echoing at the mucosal level rather than a clean route comparison. doesn’t invalidate the gut effect, just the speed delta. the sleep thing is where i’d actually park attention. did you log architecture or just duration? eight hours with under fifty minutes of deep is not eight hours of recovery, and inflammation downstream of post-antibiotic gut state fragments architecture in ways duration won’t show. if the subq arm dropped systemic inflammatory load faster than the oral did, sleep architecture is exactly where you’d see it first. worth pulling if you have ring or watch data from both cycles. ymmv.